Bull or Bear
This content is for members
Exelixis (EXEL)
Exelixis’ and Array’s Enchanting News
This content is for members
Exelixis: Further Stretching Its Cabozantinib’s Market
Exelixis (EXEL) completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® (cabozantinib) tablets for previously treated …
Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer
Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street journal report stating that Celgene …
Exelixis Strategy: Expanding the Pipeline with Novel Products
As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and …
The Year in Review Part 1
This content is for members
Exelixis: A Big Yes from the FDA
This content is for members
The Week in Review
This content is for members
Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35
This content is for members
Exelixis’ Exceptional Financial Results and Corporate Achievements
This content is for members
Exelixis: A Day for Celebrating and Learning
Two game changing news has come together on October 16, 2017, both indicating that Exelixis (EXEL) is on its way to reach its goal becoming the leader in the …
Exelixis’ and Daiichi Sankyo’s Product for Essential Hypertension Passed All the Tests
Exelixis (EXEL) announced that Daiichi Sankyo (“Daiichi Sankyo”) reported positive top-line results from a phase 3 pivotal trial of esaxerenone for …
Exelixis Is Still A Favorite
This content is for members
Some Small Outperforming Biotech Firms
This content is for members
Why Our Increased Enthusiasm for Incyte’s Product Baricitinib
This content is for members
Stocks’ Declines That Offer Real Opportunities for Accumulation at Bargain Prices
This content is for members